Mounjaro tablets in the UK: when might they arrive, and what's available now

Is there actually any oral tirzepatide product in development?

Yes, but it is not close to UK approval. Eli Lilly is running phase-three clinical trials on an oral form of tirzepatide, and early data have generated genuine interest in the research community. That interest has fed the widespread belief (a common one worth setting aside gently) that a Mounjaro tablet is almost here. It isn't. Phase-three trials take years, and after completion the data must be reviewed by regulators before any licence is granted. In the UK, that means an MHRA assessment, followed by a NICE appraisal before NHS funding could follow. For context, semaglutide was first approved as a weekly injection for weight management in the UK in 2021; its oral counterpart only reached approval in June 2026, a gap of several years even with an established injectable already on the market. Tirzepatide's oral programme is at an earlier stage. No MHRA application for an oral tirzepatide product has been publicly announced, and Eli Lilly has not confirmed a UK submission timeline. Anyone claiming a specific launch date is speculating. If you want to stay informed, the tirzepatide availability page tracks what's confirmed as it develops.

What did the MHRA actually approve in June 2026, and is it relevant here?

The MHRA's approval of Wegovy tablets on 11 June 2026 was a genuine first: the UK became the first country in Europe to licence an oral GLP-1 medicine for weight management. The drug inside the tablet is semaglutide (the same active ingredient as the Wegovy injection) reformulated with an absorption enhancer so it can be taken by mouth. It is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition, alongside a reduced-calorie diet and increased activity. The approval is directly relevant to people asking when mounjaro tablets will be available because it answers the broader question of whether regulators will licence oral GLP-1 medicines, they will, and they have. But semaglutide and tirzepatide are different molecules. The Wegovy tablet is not a Mounjaro tablet, and the two cannot be treated as interchangeable. Our guide to whether Mounjaro comes in tablet form explains the distinction clearly. Separately, a detailed look at the pill form of tirzepatide covers the research landscape without overstating what's confirmed.

What does the evidence say about injectable Mounjaro in the meantime?

While the tablet question is unresolved, the injectable form has a strong evidence base. In the SURMOUNT-1 trial (which enrolled 2,539 adults with obesity) participants taking the 15mg dose achieved an average body-weight reduction of around 20 to 21 percent over 72 weeks, a figure cited in NICE's appraisal of tirzepatide (TA1026). That recommendation, published in December 2024, means tirzepatide is now available on the NHS for qualifying patients, though eligibility criteria are strict and access is phased. For a fuller picture of how the injectable works and who it suits, the Mounjaro overview and our broader tirzepatide guide cover the mechanism, the dosing schedule and the licence in detail. For anyone exploring private access today, buying Mounjaro online through a regulated pharmacy is the legal route, a prescription is required and a prescriber must assess your suitability first. There is no shortcut around that requirement, and no tablet form that sidesteps it. The NHS tirzepatide medicines page carries patient-level information on the injection's side effects and how it's used.

So what are the realistic options if you're waiting for a tablet?

People who prefer not to inject have a licensed oral option now, even if it isn't tirzepatide. Wegovy tablets are available as a private prescription, with an escalating daily dose starting at 1.5mg and rising to a 25mg maintenance dose. Trial data from the OASIS 4 study showed an average weight loss of around 13.6 percent over 64 weeks, rising to roughly 17 percent among participants who adhered fully to the regimen. For some people that will be the right fit; for others, the injectable medicines may be more appropriate. The honest answer is that choosing between them is a clinical conversation, not a product preference. Our weight-loss treatment overview explains what's currently licensed and dispensed, and the free consultation is where a GPhC-registered prescriber reviews your situation and helps you decide. If oral tirzepatide does reach UK approval in the future, the generic tirzepatide timeline page is worth bookmarking alongside any Mounjaro tablet updates.